Fig. 2: Disease-free Survival (DFS) as per MINERVA subgroups. | Nature Communications

Fig. 2: Disease-free Survival (DFS) as per MINERVA subgroups.

From: Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Fig. 2: Disease-free Survival (DFS) as per MINERVA subgroups.

a Kaplan–Meier curves estimate DFS of the pre-categorized cohort which received adjuvant gefitinib or VP treatment (N = 171). Two-sided P value was calculated using the log-rank test. b Forest plot showing the treatment-by-interaction hazard ratio (iHR) of DFS with the cox regression model in subgroups (HTP, highly TKI-preferable group; TP, TKI-preferable group; CP, chemo-preferable group) as classified by MINERVA score. Error bars indicate 95% confidence intervals of the iHRs. c Clinical characteristics and genetic alteration spectrums of five predictive biomarkers in three MINERVA subgroups. d–f Kaplan–Meier curves of DFS for patients treated by adjuvant gefitinib or VP in three MINERVA subgroups. Black dotted lines indicate median DFS. Blue doted lines indicate 2-year survival rates (24 months). Two-sided P values were derived from the log-rank test. Exact statistical significance of DFS difference in the HTP group was 2.47 × 10−5.

Back to article page